Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-08-07
2010-11-02
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07825236
ABSTRACT:
The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
REFERENCES:
patent: 4880635 (1989-11-01), Janoff et al.
patent: 4906477 (1990-03-01), Kurono et al.
patent: 4911928 (1990-03-01), Wallach
patent: 4917951 (1990-04-01), Wallach
patent: 4920016 (1990-04-01), Allen et al.
patent: 4921757 (1990-05-01), Wheatley et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5885834 (1999-03-01), Epstein
patent: 6165789 (2000-12-01), Monia et al.
patent: 6348450 (2002-02-01), Tang et al.
patent: 7022849 (2006-04-01), Pitts et al.
patent: 2003/0045490 (2003-03-01), Dale et al.
patent: 2003/0220273 (2003-11-01), Bennett et al.
patent: 97/35989 (1997-10-01), None
patent: 99/66037 (1999-12-01), None
patent: 00/40714 (2000-07-01), None
patent: 02/22661 (2002-03-01), None
patent: 03/012030 (2003-02-01), None
Essayan, DM, “Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors and and Immunomodulation.” Biochemical Pharmacology 57:965-973, 1999.
Perry, MJ and Higgs, GA, “Chemotherapeutic potential of phosphodiesterase inhibitors.” Current Opinion in Chemical Biology 2:472-481, 1998.
Bundschuh, DS et al., “In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor.” The Journal of Pharmacology and Experimental Therapeutics 297(1):280-290, 2001.
Burnouf, C and Pruniaux, M-P, “Recent Advances in PDE4 Inhibitors as Immunoregulators and Anti-Inflammatory Drugs.” Current Pharmaceutical Design 8:1255-1296, 2002.
Giembycz, MA, “Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.” Expert Opin Investig Drugs 10(7):1361-1379, 2001.
Torphy, TJ, “Phosphodiesterase Isozymes.” Am J Respir Crit Care Med 157:351-370, 1998.
Au, B-T et al., “Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.” British Journal of Pharmacology 123:1260-1266, 1998.
Compton, CH et al., “Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.” The Lancet 358:265-270, 2001.
Ma, D et al., “Phosphodiesterase 4B Gene Transcription Is Activated by Lipopolysaccharide and Inhibited by Interleukin-10 in Human Monocytes.” Molecular Pharmacology 55:50-57, 1999.
Wang, P et al., “Phosphodiesterase 4B2 Is the Predominant Phosphodiesterase Species and Undergoes Differential Regulation of Gene Expression in Human Monocytes and Neutrophils.” Molecular Pharmacology 56:170-174, 1999.
Churg, A et al., “Acute Cigarette Smoke-Induced Connective Tissue Breakdown Requires both Neutrophils and Macrophage Metalloelastase in Mice.” Am J Respir Cell Mol Biol 27:368-374, 2002.
Churg, A et al., “Tumor Necrosis Factor-alpha Is Central to Acute Cigarette Smoke-induced Inflammation and Connective Tissue Breakdown.” Am J Respir Crit Care Med 166:849-854, 2002.
Gaede, Ki et al., “Analysis of differentially regulated mRNAs in monocytic cells induced by in vitro stimulation.” J Mol Med 77:847-852, 1999.
Kebelmann-Betzing, C et al., “Charaterization of Cytokine, Growth Factor Receptor, Costimulatory and Adhesion Molecule Expression Patterns of Bone Marrow Blasts in Relapsed Childhood B Cell Precursor All.” Cytokine 13 (1):39-50, 2001.
Ishii, Y et al., “Induction of Matrix Metalloproteinase Gene Transcription by Nitric Oxide and Mechanisms of MMP-1 Gene Induction in Human Melanoma Cell Lines.” Int J Cancer 103:161-168, 2003.
Müller, T et al., “Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition.” TiPS 17:294-298, 1996.
Weintraub, HM, “Antisense RNA and DNA.” Scientific American 262(1):40-46, 1990.
Némoz, G et al., “Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells.” FEBS Letters 384:97-102, 1996.
Wang, P et al., “Cloning, Characterization, and Tissue Distribution of Mouse Phosphodiesterase 7A1.” Biochemical and Biophysical Research Communications 276:1271-1277, 2000.
Clayton, RA et al., “The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma.” Respiratory Research 5:4(1-9), 2004.
McCluskie, K et al., “Phosphodiesterase type 4 inhibitors cause pro-inflammatory effects in vivo.” American Society for Pharmacology and Experimental Therapeutics JPET #105080, 2006.
Smith, SJ et al, “Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes.” Molecular Pharmacology 66:1679-1689, 2004.
Robichaud, A et al., “Deletion of phosphodiesterase 4D in mice shortens alpha2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.” J Clin Invest 110:1045-1052, 2002.
Robichaud, A et al., “Assessing the emetic potential of PDE4 inhibitors in rats.” British Journal of Pharmacology 135:113-118, 2002.
Calverley, PMA et al, “Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease.” Am J Respir Crit Care Med 176:154-161, 2007.
Dietsch, GN et al., “Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity.” Toxicologic Pathology 34:39-51, 2006.
Epstein, Methods: A Companion to Methods in Enzymology, Article No. ME970562, 14:21-33 (1998). “Antisense Inhibition of Phosphodiesterase Expression.”
Li et al., Science, 283:848-851 (1999). “CD3- and CD28-Dependent induction of PDE7 Required for T-Cell Activation.”
MacKenzie et al., Proc National Academic Science, USA, 95:3549-3554 (1998). “Stimulation of p70S6 Kinase Via a Growth Hormone-Controlled Phosphatidylinositol 3-Kinase Pathway Leads to the Activation of a PDE4A Cyclic AMP-Specific Phosphodiesterase in 3T3-F442A Preadipocytes.”
Soderling et al., Current Opinion in Cell Biology, 12:174-179 (2000). “Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions.”
D'Anjou Helene
Renzi Paolo
Zemzoumi Khalid
Chong Kimberly
Nixon & Peabody LLP
Topigen Pharmaceutique Inc.
LandOfFree
Oligonucleotide compositions and methods for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide compositions and methods for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide compositions and methods for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248760